Synereca Pharmaceuticals

Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. Its portfolio includes prototypic RecA inhibitors, which target various pathogenic bacteria/E. coli, including those responsible for lung, urinary tract, and skin infections, as well as weaponizable gram-